The purpose of this study is to identify a dose of P276-00 that can be safely administered
along with Radiation and to examine safety and efficacy of the combination in treatment of
advanced head and neck cancer.
Radiation: External beam radiotherapy (EBRT)
We will connect you to the doctor responsible for this trial and help you get more information.
Locations near you
Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Full eligibility criteria for NCT00899054
Ages eligible for Study
18 Years and older
Genders eligible for Study
Accepts Healthy Volunteers
Phase I component: Radiation naïve subjects with histologically and/ or cytologically confirmed squamous cell carcinoma of head and neck that is non-metastatic, unresectable and recurrent. Radiation naïve subjects with non-recurrent, non-metastatic, unresectable, disease can also be enrolled if he/she is intolerant to and/or unwilling for chemoradiotherapy involving standard cytotoxic agents (e.g. cisplatin, carboplatin, oxaliplatin, 5-FU, taxanes, methotrexate, etc)
Phase II component: Radiation naïve subjects with non-recurrent, non-metastatic, unresectable, locally advanced squamous cell carcinoma of head and neck who are intolerant to and/or unwilling for chemoradiotherapy involving standard cytotoxic agents (e.g. cisplatin, carboplatin, oxaliplatin, 5-FU, taxanes, methotrexate, etc).
Phase I Component: subjects must not have received any treatment (chemotherapy, targeted or biologic agents, radiotherapy, surgery etc) for the recurrent disease.
Phase II Component: The subjects must not have been curatively operated for the disease.
Subjects must have completed any prior chemotherapy, biologic/targeted anti-cancer therapy or surgery at least 4 weeks (at least 6 weeks for nitrosureas and mitomycin C) before initiation of protocol treatment and subjects must have recovered (to < or = grade 1) from the toxic effects from any prior therapy
Measurable disease as per RECIST criteria.
Age > or = 18 years
ECOG (Eastern Cooperative Oncology Group) performance status < or = 2
Life expectancy of at least 12 weeks
Normal organ and marrow function:
Hemoglobin > or = 100 g/L
Leukocytes > or = 3 x 109/L
Absolute Neutrophil Count (ANC)> or = 1.5 x 109/L
Platelets > or = 75 x 109/L
Total bilirubin < or = 1.5 X institutional Upper Limit of Normal (ULN)
AST(SGOT)< or = 2.5 X institutional ULN
ALT(SGPT)< or = 2.5 X institutional ULN
Creatinine < or = 1.5 X institutional ULN
Ability to understand and willingness to sign a written informed consent document.
Subjects who had received any other investigational drug within 1 month prior to day 1 of study drug administration or who have not recovered (to < or = grade 1) from adverse effects of the investigational agent received prior to this period.
History of unstable angina or myocardial infarction or stroke within 6 months prior to initiation of protocol treatment.
QTcF > 450 msec
Subjects with uncontrolled inter-current illness including, but not limited to active infection, symptomatic congestive heart failure, cardiac arrhythmia, psychiatric illness or any condition that would limit compliance with study requirements.
Subjects known to be suffering from infection with HIV, Tuberculosis, Hepatitis C or Hepatitis B.
Women who are pregnant or lactating.
Women of childbearing potential [defined as a sexually mature woman who has not undergone hysterectomy or who has not been naturally postmenopausal for at least 24 consecutive months (i.e. who has had menses any time in the preceding 24 consecutive months)] and men, not agreeing to use at least two approved methods of contraception, including at least one barrier method prior to study entry (after signing the informed consent document), during the duration of study participation and for at least 4 weeks after withdrawal from the study drug, unless they are surgically sterilised.
Any condition, including laboratory abnormalities, that in the opinion of the investigator places the subject at an unacceptable risk or deems the subject not suitable for participation in the study.
All locations for NCT00899054
Government Medical College
Aurangabad, Maharashtra, India, 431001
Curie Manavata Cancer Center
Nashik, Maharashtra, India, 422 004
Bhagwan Mahawir Cancer Hospital & Research Centre
Jaipur, Rajasthan, India, 302017
V. N. Cancer Centre, GKNM Hospital
Coimbatore, Tamil Nadu, India, 641037
Meenakshi Mission Hospital & Research Centre
Madurai, Tamil Nadu, India, 625107
Christian Medical College
Vellore, Tamil Nadu, India, 632 004
View full eligibility
Tris trial is registered with FDA with number: NCT00899054. The sponsor of the trial is Piramal Enterprises Limited and it is looking for 23 volunteers for the current phase.
Official trial title: An Open Label, Multicenter Phase I/II Study Of Selective Cyclin Dependent Kinase Inhibitor P276-00 In Combination With Radiation In Subjects With Recurrent And/Or Locally Advanced Squamous Cell Carcinoma Of Head And Neck
1What's a trial
4Get in touch
What's a trial
Not sure you're well informed about clinical trials? Learn more about their benefits, risks and other important details.
Enter your details like condition, age, gender and other preferences and we will show you a list of all relevant clinical trials.
Review the summary of the selected clinical trial and all the locations near you in order to see if it's of interest to you.
Get in touch
You've found an interesting trial? We'll need a bit more information about you so we can connect you to the doctor in charge.
Thank you for applying!
We'll contact you soon with more information.
FindMeCure is constantly improving its search. Take part in it and help millions by filling our patients' survey!